T-Cell Non-Hodgkin Lymphoma — Trials

T-Cell Non-Hodgkin Lymphoma — Trials · CancerIndex

Clinical trials

Registered studies

1,008 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 225
Recruiting: 127
Ph III recruiting: 9
Growth YoY: +23.4%
Industry share: 21%
Top sponsor: Institute of Hematology & Blood Diseases Hospital, China
Termination share: 35.1%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (169)

clinicaltrialsPublishedShowing 401–450 of 519 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT02533323	P-Gemox Regimen as First-line Chemotherapy in NK/T Lymphoma Patiens	terminated	Phase 2	50	Sun Yat-sen UniversityOTHER	1	May 9, 2018	clinicaltrials
NCT00807495	Study of Alisertib (MLN8237) in Adults With Aggressive Non-Hodgkin's Lymphoma	completed	Phase 2	48	Millennium Pharmaceuticals, Inc.INDUSTRY	1	Mar 27, 2018	clinicaltrials